Founded in 2000, Landing Med is a medtech company focused on early cancer detection solutions. We offer affordableAI-powered cytology and digital pathology technologies to empower laboratories worldwide to enhance diagnostic precision, efficiency, and confidence. As a globally recognized leader in cervical cytology screening, we have successfully screened over 10 million women and strive to make pathology accessible to all.
Cost-effectiveness of artificial intelligence-
assisted liquid-based cytology testingfor
cervical cancer screening in China
The artificial intelligence-assisted cytology diagnostic system in large-scale cervical cancer screening: A population-based cohort study of 0.7 million women
Cervical cancer screening aided by artificial
intelligence, China
Artificial intelligence-assisted cytology for
detection of cervical intraepithelial neoplasia
or invasive cancer: A multicenter, clinical-
based, observational study
“China’s population-based AI-assisted cervical cytology screening technology was pioneered by Landing Med and their AI model remains the most validated in the country.”
“Landing Med’s revolutionary end-to-end AI-powered cervical cancer screening model gives China hope to achieve the 2030 WHO cervical cancer elimination strategy. Countries with high demand for screening but limited cytopathology resources, such as low and middle-income countries, can consider AI-assisted solutions like Landing Med’s.”
“Landing Med’s DNA ploidy technology for oral cancer primary diagnosis is well proven and effective.”
“Landing Med is China’s benchmark for population-based cervical cancer screening.”
“Landing Med has made AI and digital pathology accessible for rural clinics. Macheng Maternal and Child’s Health Care Clinic can offer telepathology solutions so patients don’t need to travel hundreds of kilometers to consult pathologists in big cities thanks to Landing Med’s innovative and affordable solutions.”
Chinese Medtech Company Landing Med Surpasses 10 Million AI-Assisted Pap Smear Screenings
January 19, 2024
Landing Med, a Chinese medtech company focused on early cancer detection, has achieved a significant milestone by completing over 10 million cervical cancer screenings using artificial intelligence (AI).
ANTH, Landing Med introducing AI-based
screening for Cervical Cancer in Pakistan
November 20, 2023
Islamabad, (Parliament Times) : In a landmark move towards improving cancer care, Dr. Akbar Niazi Teaching Hospital (ANTH) in Islamabad, Pakistan, has joined forces with Landing Med
China to provide technology for cervical cancer
screening
November 21, 2023
ISLAMABAD: A hospital of federal capital has joined hands with Landing Med, medical technology company, based in Wuhan China, to make use of the artificial intelligence (AI) in advancing cervical cancer screening.
Let’s get in touch
Quick menu
